An update on the overall survival of a real world retrospective study – PACIFIC-R
PACIFIC-R STUDY DESIGN1
PATIENT CHARACTERISTICS
PACIFIC-R OS OUTCOME: MORE THAN 60% OF PATIENTS WERE ESTIMATED TO BE ALIVE AT 3 YEARS
OUTCOMES BY PD-L1 STATUS
Reference: 1. Girard, N. et al (2022), 58O - Real world overall survival with durvalumab after chemoradiotherapy in patients with unresectable stage III non small cell lung cancer (NSCLC): interim analysis from the Pacific-R study, Presented in ESMO-IO 2022.